Servier announced a $2.5 billion cash acquisition of Day One Biopharmaceuticals to add rare oncology programs, including pediatric low‑grade glioma candidates, strengthening its rare‑cancer strategy. The agreed price represents a substantial premium and aligns with Servier’s push to scale targeted oncology assets through acquisition and global development expertise. In parallel, Teva secured up to $400 million in growth capital from Blackstone Life Sciences to accelerate late‑stage development of duvakitug, an anti‑TL1A monoclonal antibody for inflammatory bowel disease, with potential regulatory and commercial milestones and royalty arrangements attached. Both transactions underscore continued private‑market willingness to fund late‑stage development and to consolidate rights to specialized pipelines across oncology and immune‑mediated diseases. Named sources: Servier and Teva press releases and associated deal documentation. For context: such strategic acquisitions and growth‑capital arrangements are common tactics for established pharma to access innovation while managing risk and capital deployment.